Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Recruiting now · Phase 3

Conditions studied: Paroxysmal Nocturnal Haemoglobinuria (PNH)

In brief

The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.

Key facts

Study ID
NCT06932744
Run by
Wuhan Createrna Science and Technology Co., Ltd
People needed
66
Starts
2024-08-30
Expected to finish
2025-12-30
Last updated by the study team
2025-05-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.